about
miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilizationEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideInhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugsInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortEpidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort.Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response.Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndromeIncidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndromeNCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndromeBruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry.Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study.Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.Sjogren's syndrome is associated with and not secondary to systemic sclerosis.Dendritic cells and interferon-mediated autoimmunity.Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndromeRituximab: a new therapeutic alternative in rheumatoid arthritis.Microparticle-induced release of B-lymphocyte regulators by rheumatoid synoviocytesCognitive Dysfunction and Dementia in Primary Sjögren's Syndrome.X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's SyndromeMarkers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases.Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activityAbatacept therapy and safety management.Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept
P50
Q21135455-91A04262-7E02-4324-B278-98F16E9171EBQ26778262-BDB88791-456D-46F0-AFF2-EF683B762646Q28167625-B3BD25F0-31DF-4111-A79C-D1DA72AD533AQ30234696-49F3BFB7-F4AD-4847-ABAA-0E036218BA84Q30948155-4F8125AA-D026-449F-B170-C0D670CC657CQ31038073-D1326C7E-EB44-421B-83EB-A7FEC1131A07Q31083973-C1236690-C457-48A2-AACA-E69A9381AFD7Q31145428-CDC24EEE-50AA-42FC-A1AB-D7D9036B22BFQ31152756-AA42EFA9-2058-4D95-81DC-D9D12CE87D6DQ33349381-FCDFF76B-6CC7-4754-BCD4-FEEA245F96DFQ33372523-1D5545EB-3208-4EC2-A0E3-A53BB6600123Q33767771-A81DBDD5-57B9-4C92-A0A3-0F3C829AAA53Q34117422-DBBC0A4F-41BF-4F48-BD08-E1610B4D79BEQ34233372-EF94AF95-CE6E-4B76-AA73-026FCEC41AE6Q34381180-2AC880EE-0746-4DD4-911D-78EEDE1196C2Q34434727-8A1C8C06-C0E5-4268-A347-C73235F95F3DQ34479625-6CB9ACD9-B166-41AB-8EB8-2D243D61FFF0Q34541173-1E75F74B-09A2-488F-B5AD-5867F3888216Q34663199-5D3E2D90-AFFC-4C78-9706-A51C1EA264DCQ34743817-CF8BF370-1D15-427E-9EB1-A50105579484Q34896464-A555E267-95EC-485D-BA26-30780CC2B1FCQ34973908-FDD28898-D088-4AF8-A3BB-ED30FA918982Q35774612-88B32231-C88C-449A-BCE9-E765686EB55DQ35953204-202325DD-AE55-4177-9BB2-01768102135FQ35953373-A0468E65-AD8C-4EA2-821F-89054171B538Q35974381-743C059D-DADD-43B2-B491-6CCFF6DC02A5Q36009254-5C2A9478-E0FB-48A1-9F75-C3DF6757DD40Q36070691-9D481969-1737-4C9D-93C0-9D434CF0DA1FQ36551164-6737CB1E-0EC8-4757-8734-B4866A7C835AQ36846871-854B050C-5E0B-4275-B81F-D00F387FF307Q37083442-A7265CF5-F4FB-42AE-993F-42AE8B807CA3Q37197613-CCB1F83F-8453-4628-B8FC-AB97108E39A2Q37206923-10132803-A279-4694-A041-8DC53687D455Q37221887-E2776D5A-35BA-4260-81BA-51295D10E69AQ37249179-C60226D3-1BE3-4882-8CA0-4BDECFCA1518Q37350904-ED078EF2-F23E-4FCB-B60A-9738FEE76482Q37452801-C06DAE7C-55DC-49F3-A876-7BCAAB882862Q37454013-DBF3654A-041A-46A4-8AEF-DA7093661A47Q37533319-7BB71F7F-7D36-4CE7-BE41-8A3476A82D3AQ37696041-0739D92A-9652-4EC9-9400-1C4408261F9D
P50
name
Jacques-Eric Gottenberg
@ast
Jacques-Eric Gottenberg
@en
Jacques-Eric Gottenberg
@es
Jacques-Eric Gottenberg
@nl
type
label
Jacques-Eric Gottenberg
@ast
Jacques-Eric Gottenberg
@en
Jacques-Eric Gottenberg
@es
Jacques-Eric Gottenberg
@nl
prefLabel
Jacques-Eric Gottenberg
@ast
Jacques-Eric Gottenberg
@en
Jacques-Eric Gottenberg
@es
Jacques-Eric Gottenberg
@nl
P214
P21
P214
P31
P7859
viaf-208209178